Compositions comprising dimethyl sulfoxide (DMSO)
AssigneeAbela Pharmaceuticals, Inc.
InventorJack De La Torre
Life of this patent
Estimating the term…
Abstract
The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses are also provided.
Claims24
A method of treating brain injury, the method consisting essentially of:
- administering a composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine and one or more pharmaceutically-acceptable carriers to a brain injury patient,
- wherein the DMSO is present in a concentration range of about 20% to about 40% in the composition,
- wherein the L-arginine is present in a range of about 0.5% to about 10% weight per volume of the composition,
- wherein the administering is intravenous, and
- wherein the brain injury is a spinal cord injury or a traumatic brain injury.
A method of treating a patient with brain injury, said method comprising:
- obtaining a composition comprising dimethylsulfide (DMS) and L-arginine in a therapeutically effective dose,
- wherein said therapeutically effectively dose of DMS is a concentration of about 20% to 40% of said composition and said therapeutically effective dose of L-arginine is about 0.5% to about 10% weight per volume of said composition;
- and
- administering said composition intravenously to said patient, wherein said brain injury is a spinal cord injury or a traumatic brain injury.
A method of increasing blood flow in the central nervous system, consisting essentially of:
- intravenously administering a therapeutically effective dose of a pharmaceutical composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine, and one or more pharmaceutically-acceptable carriers to a subject having a spinal cord injury or a traumatic brain injury.
A method of treating brain injury, consisting essentially of:
- administering a therapeutically effective dose of a pharmaceutical composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine, urea, and one or more pharmaceutically-acceptable carriers
- to an individual having a brain injury, wherein said brain injury comprises a spinal cord injury or a traumatic brain injury.
A method of treating brain injury, the method consisting essentially of:
- administering a composition consisting essentially of DMSO, L-arginine and one or more pharmaceutically-acceptable carriers to a brain injury patient,
- wherein said DMSO is present in a concentration range of about 20% to about 40% in the first composition,
- wherein said L-arginine is present in a range of about 0.5% to about 10% weight per volume of said first composition,
- wherein said brain injury is a spinal cord injury or a traumatic brain injury.
A method of treating brain injury, consisting essentially of:
- administering a therapeutically effective dose of a pharmaceutical composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine, MSM, and one or more pharmaceutically-acceptable carriers
- to an individual having a brain injury, wherein said brain injury comprises a spinal cord injury or a traumatic brain injury.
A method of treating brain injury, comprising:
- administering a therapeutically effective dose of a composition comprising dimethylsulfide (DMS), L-arginine, MSM, and one or more pharmaceutically-acceptable carriers to an individual having a brain injury, wherein said brain in jury comprises a spinal cord injury or a traumatic brain injury.
A method of treating brain injury, comprising:
- administering a therapeutically effective dose of a pharmaceutical composition comprising dimethylsulfide (DMS), L-arginine, urea, and one or more pharmaceutically-acceptable carriers to an individual having a brain injury, wherein said brain injury comprises a spinal cord injury or a traumatic brain injury.
A method, comprising:
- administering a composition to a patient, the composition consisting essentially of:
- dimethylsulfoxide (DMSO),
- at least one of L-arginine, L-lysine, L-aspartate, dimethylsulfide (DMS), methylsulfonylmethane (MSM), and urea, and
- one or more pharmaceutically-acceptable carriers.
A method, comprising:
- administering a composition to a patient, the composition comprising:
- dimethylsulfide (DMS),
- at least one of L-arginine, L-lysine, L-aspartate, dimethylsulfoxide (DMSO), methylsulfonylmethane (MSM), and urea, and
- one or more pharmaceutically-acceptable carriers.
Dependencies are inferred from the claim text.